Phase II trial of carboplatin and paditaxel in papillary renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 7, Issue 1, 2009, Pages 39-42

  Bylow, Kathryn A ^a,c   Atkins, Michael B ^b   Posadas, Edwin M ^a   Stadler, Walter M ^a   McDermott, David F ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

C met pathway inhibitors; Leukopenia; Neutropenia; Non clear cell carcinoma

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY COLLECTING TUBULE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; PHASE 2 CLINICAL TRIAL; SEIZURE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65249089759     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.007     Document Type: Article

References (22)

1. Reuter VE, Presti JC Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000; 27:124-137.
2. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004; 11:71-77.
3. (Pubitemid 34441667) Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376-81.
4. (Pubitemid 37108098) Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003; 170:1141-5.
5. (Pubitemid 46849157) Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81.
6. Lindor NM, Dechet CB, Greene MH, et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001; 5:101-106.
7. (Pubitemid 32565343) Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-7.
8. Mai KT, Landry DC, Robertson SJ, et al. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Pathol Res Pract 2001; 197:671-675.
9. (Pubitemid 47206766) Yamishita S, Ioritani N, Oikawa K, et al. Morphological subtyping of papillary renal cell carcinoma: Clinicopathological characteristics and prognosis. Int J Urol 2007; 14:679-83.
10. (Pubitemid 26333032) Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595-9.
11. (Pubitemid 34525785) Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62:2957-61.
12. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferonalpha (IFN). J Clin Oncol 2007; 25 (18 suppl) :243s (Abstract 5033).
13. (Pubitemid 27198158) Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
14. Stadler WM. Therapeutic options for variant renal cancer: a true orphan disease. Clin Cancer Res 2004; 10:6393S-6396S.
15. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma (RCC) in response to IL-2 based therapy. Proc Am Soc Clin Oncol 2003; 22:851 (Abstract 3420).
16. (Pubitemid 44845616) Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006; 107:2617-21.
17. Gollob JA, Upton MP, DeWolf WC, et al. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058.
18. (Pubitemid 46166311) Maestroni U, Ferretti S, Dinale F, et al. A renal cancer with intermediate characteristics between collecting (Bellini) duct carcinoma and urothelial carcinoma: case report and review of the literature. Tumori 2006; 92:545-8.
19. (Pubitemid 29136194) Pycha A, Grbovic M, Posch B, et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 1999; 53:510-5.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
21. National Institutes of Health: National Cancer Institute Common Toxicity Criteria version 2. Available at: http://ctep.info.nih.gov/CTC3/ctc-ind-term. htm. Accessed: March 15, 2008.
22. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.